Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576871 · ClinicalTrials.gov registry record · Early Phase 1
Re-treatment 225Ac-J591 for mCRPC
A Early Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT04576871: Completed Early Phase 1 study, sponsored by Weill Medical College of Cornell University.
NCT04576871 is a Early Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04576871, a Early Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if re-treatment with 225Ac-J591 can be given without severe side effects.
Primary Outcome
Proportion of subjects with dose-limiting toxicity (DLT) from treatment cycle 1 to the end of the safety evaluation period at the end of the study. Acceptable safety is determined if no more than 2 (33%) of the subjects in a cohort experience DLT.
Interventions
- DRUG 225Ac-J591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2024-05-31 |
| Phase | Early Phase 1 |
What the finished NCT04576871 record still lists
NCT04576871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which 225Ac-J591 is the first listed.
NCT04576871 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04576871 about?
NCT04576871 is a clinical study titled "Re-treatment 225Ac-J591 for mCRPC". The purpose of this study is to find out if re-treatment with 225Ac-J591 can be given without severe side effects.
What is the current status of trial NCT04576871?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2020-10-29. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT04576871?
The interventions under investigation include: 225Ac-J591 (DRUG).
Who is sponsoring clinical trial NCT04576871?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04576871's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI